ResMed’s fiscal first quarter paired steady demand with stronger product economics, yet the market’s immediate reaction was sharply negative. Core constant-currency revenue grew 7%, GAAP gross margin reached 61.5%, and the stock declined 9.05% in the next regular session. That contrast makes the next phase less about one quarter’s headline and more about whether execution remains durable.
Revenue reached $1.415 billion and GAAP diluted earnings per share reached $2.92. Sleep and Breathing Health produced $1.260 billion of revenue, while Residential Care Software generated $155 million. The mix confirms that the device franchise remains the larger business engine, with software providing a smaller second source of activity.
Cash flow remained substantial. Operating cash flow was $422 million and free cash flow was $374 million. At September 30, cash was $1.011 billion, compared with $160 million of current debt and $250 million of long-term debt. This liquidity provides flexibility, even as inventory of $1.021 billion remains an important item for later filings.
The margin picture was mixed rather than uniformly stronger. Gross margin improved, but GAAP operating margin fell to 32.0% from 33.4%. Free cash flow also declined from $414 million in the comparable period. The gap between product economics and overall operating leverage is one of the clearest issues for subsequent results.
Visibility is also incomplete. The October 29 release displayed fiscal 2027 ranges originally issued on August 6 but did not provide a fresh fiscal-year range. Later company updates can clarify whether growth, operating spending, inventory, and cash conversion remain aligned after the post-results repricing.
The full ResMed premium review examines the underlying fundamentals, risk factors, and the questions the next report needs to answer.
Market analysis, not personalized investment advice.